Literature DB >> 19794230

L-valine ester of cyclopropavir: a new antiviral prodrug.

Zhimeng Wu1, John C Drach, Mark N Prichard, Milka Yanachkova, Ivan Yanachkov, Terry L Bowlin, Jiri Zemlicka.   

Abstract

BACKGROUND: Following the example of L-valine prodrugs of antiviral nucleoside analogues, L-valine ester of cyclopropavir (valcyclopropavir) was synthesized.
METHODS: The known tetrahydropyranylcyclopropavir was transformed to N-(tert-butoxycarbonyl)-L-valine ester, which was deprotected to valcyclopropavir.
RESULTS: Stability of valcyclopropavir towards hydrolysis at pH 7.0 roughly corresponded to that of valganciclovir. Valcyclopropavir inhibited replication of human cytomegalovirus (HCMV, Towne and AD169 strains) to approximately the same extent as the parent drug cyclopropavir. Pharmacokinetic studies in mice established that the oral bioavailability of valcyclopropavir was 95%.
CONCLUSIONS: The prodrug valcyclopropavir offers some improved therapeutic parameters over the parent compound cyclopropavir.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19794230      PMCID: PMC2931272          DOI: 10.3851/IMP782

Source DB:  PubMed          Journal:  Antivir Chem Chemother        ISSN: 0956-3202


  12 in total

1.  Reactivity of valganciclovir in aqueous solution.

Authors:  Dimitrios Stefanidis; Michael Brandl
Journal:  Drug Dev Ind Pharm       Date:  2005-10       Impact factor: 3.225

Review 2.  Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections.

Authors:  D Ormrod; L J Scott; C M Perry
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

3.  Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine.

Authors:  Claire Pierra; Agnès Amador; Samira Benzaria; Erika Cretton-Scott; Marc D'Amours; John Mao; Steven Mathieu; Adel Moussa; Edward G Bridges; David N Standring; Jean-Pierre Sommadossi; Richard Storer; Gilles Gosselin
Journal:  J Med Chem       Date:  2006-11-02       Impact factor: 7.446

4.  Valganciclovir.

Authors:  M Curran; S Noble
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  A novel nucleoside prodrug-activating enzyme: substrate specificity of biphenyl hydrolase-like protein.

Authors:  Insook Kim; Xueqin Song; Balvinder S Vig; Sachin Mittal; Ho-Chul Shin; Philip J Lorenzi; Gordon L Amidon
Journal:  Mol Pharm       Date:  2004 Mar-Apr       Impact factor: 4.939

6.  Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections.

Authors:  Earl R Kern; Deborah J Bidanset; Caroll B Hartline; Zhaohua Yan; Jiri Zemlicka; Debra C Quenelle
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

7.  Antiviral L-nucleosides specific for hepatitis B virus infection.

Authors:  M L Bryant; E G Bridges; L Placidi; A Faraj; A G Loi; C Pierra; D Dukhan; G Gosselin; J L Imbach; B Hernandez; A Juodawlkis; B Tennant; B Korba; P Cote; P Marion; E Cretton-Scott; R F Schinazi; J P Sommadossi
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

Review 8.  Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections.

Authors:  C M Perry; D Faulds
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

9.  Synthesis and antiviral activity of (Z)- and (E)-2,2-[bis(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines: second-generation methylenecyclopropane analogues of nucleosides.

Authors:  Shaoman Zhou; Julie M Breitenbach; Katherine Z Borysko; John C Drach; Earl R Kern; Elizabeth Gullen; Yung-Chi Cheng; Jiri Zemlicka
Journal:  J Med Chem       Date:  2004-01-29       Impact factor: 7.446

10.  Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2.

Authors:  M E Ganapathy; W Huang; H Wang; V Ganapathy; F H Leibach
Journal:  Biochem Biophys Res Commun       Date:  1998-05-19       Impact factor: 3.575

View more
  6 in total

Review 1.  The search for new therapies for human cytomegalovirus infections.

Authors:  Mark N Prichard; Earl R Kern
Journal:  Virus Res       Date:  2010-11-21       Impact factor: 3.303

Review 2.  Cytomegalovirus antivirals and development of improved animal models.

Authors:  Alistair McGregor; K Yeon Choi
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-09-01       Impact factor: 4.481

3.  Synthesis and antiviral activities of methylenecyclopropane analogs with 6-alkoxy and 6-alkylthio substitutions that exhibit broad-spectrum antiviral activity against human herpesviruses.

Authors:  Mark N Prichard; John D Williams; Gloria Komazin-Meredith; Atiyya R Khan; Nathan B Price; Geraldine M Jefferson; Emma A Harden; Caroll B Hartline; Norton P Peet; Terry L Bowlin
Journal:  Antimicrob Agents Chemother       Date:  2013-05-13       Impact factor: 5.191

4.  Potential Development of Tumor-Targeted Oral Anti-Cancer Prodrugs: Amino Acid and Dipeptide Monoester Prodrugs of Gemcitabine.

Authors:  Yasuhiro Tsume; Adam J Drelich; David E Smith; Gordon L Amidon
Journal:  Molecules       Date:  2017-08-10       Impact factor: 4.411

Review 5.  Highlights in antiviral drug research: antivirals at the horizon.

Authors:  Erik De Clercq
Journal:  Med Res Rev       Date:  2012-05-02       Impact factor: 12.944

Review 6.  Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy.

Authors:  Morgan Hakki
Journal:  Curr Hematol Malig Rep       Date:  2020-04       Impact factor: 4.213

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.